We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Moleculin Biotech (MBRX) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Moleculin Biotech (MBRX - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of MBRX and the rest of the Medical group's stocks.
Moleculin Biotech is a member of the Medical sector. This group includes 887 individual stocks and currently holds a Zacks Sector Rank of #1. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. MBRX is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for MBRX's full-year earnings has moved 26.97% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, MBRX has returned 19.11% so far this year. At the same time, Medical stocks have lost an average of 1.63%. This shows that Moleculin Biotech is outperforming its peers so far this year.
Looking more specifically, MBRX belongs to the Medical - Biomedical and Genetics industry, which includes 381 individual stocks and currently sits at #39 in the Zacks Industry Rank. On average, this group has gained an average of 8.58% so far this year, meaning that MBRX is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track MBRX. The stock will be looking to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Moleculin Biotech (MBRX) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Moleculin Biotech (MBRX - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of MBRX and the rest of the Medical group's stocks.
Moleculin Biotech is a member of the Medical sector. This group includes 887 individual stocks and currently holds a Zacks Sector Rank of #1. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. MBRX is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for MBRX's full-year earnings has moved 26.97% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, MBRX has returned 19.11% so far this year. At the same time, Medical stocks have lost an average of 1.63%. This shows that Moleculin Biotech is outperforming its peers so far this year.
Looking more specifically, MBRX belongs to the Medical - Biomedical and Genetics industry, which includes 381 individual stocks and currently sits at #39 in the Zacks Industry Rank. On average, this group has gained an average of 8.58% so far this year, meaning that MBRX is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track MBRX. The stock will be looking to continue its solid performance.